AUTL

Autolus Therapeutics plc

Price Chart

Latest Quote

$1.51

+0.02 (+1.34%)

Current Price

Previous Close	$1.49
Open	$1.49
Day High	$1.53
Day Low	$1.48
Volume	154,206

Fetched: 2026-06-17T14:36:54

Stock Information

Shares Outstanding	266.14M
Cash Equivalents	$217.45M
Revenue	$1.08M
Net Income	$-53.28M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$401.88M
EPS (TTM)	$-1.09
Exchange	NMS

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$-158.79M
Sales	$1.08M
Income	$-53.28M
Book/sh	$5.91
Cash/sh	$0.82
Employees	752

Financial Ratios

Quick Ratio	10.32
Current Ratio	11.05

Returns & Margins

ROA	-22.27%
ROE	-29.62%
Operating Margin	-6570.75%

Ownership

Insider Ownership	18.08%
Institutional Ownership	76.21%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-2.40
P/S	372.63
P/B	0.26

Analyst Data

Recommendation	strong_buy
Target Price	$8.71

Technical Indicators

SMA20	$1.63
SMA50	$1.58
SMA200	$1.53
RSI	40.00
ATR	0.1266

Shares Float	33.90M
Short Float	7.41%
Short Ratio	7.56
Rel Volume	0.12

Performance History

Week	+3.42%
Month	-7.36%
Quarter	+0.00%
6 Months	-6.21%
YTD	-19.25%
Year	-28.77%
3 Years	-47.39%
5 Years	-77.60%
10 Years	-93.96%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-17	$1.51	154,206
2026-06-15	$1.50	1,275,500
2026-06-12	$1.56	1,019,500
2026-06-11	$1.56	923,500
2026-06-10	$1.48	890,700
2026-06-09	$1.46	1,567,500
2026-06-08	$1.46	1,536,900
2026-06-05	$1.53	1,461,900
2026-06-04	$1.66	1,272,800
2026-06-03	$1.62	2,063,900
2026-06-02	$1.75	1,167,200
2026-06-01	$1.84	1,531,300
2026-05-29	$1.87	2,402,000
2026-05-28	$1.77	1,608,300
2026-05-27	$1.68	1,528,500
2026-05-26	$1.68	1,071,000
2026-05-22	$1.70	1,037,700
2026-05-21	$1.65	668,600
2026-05-20	$1.62	924,900
2026-05-19	$1.63	1,709,300
2026-05-18	$1.80	5,951,300

About Autolus Therapeutics plc

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

📰 Latest News

European Equities Traded in the US as American Depositary Receipts Slightly Higher in Tuesday Trading

MT Newswires • 2026-06-16T15:08:44Z

European Equities Traded in the US as American Depositary Receipts Increase in Friday Trading; Rise for Week

MT Newswires • 2026-06-12T15:14:33Z

European Equities Traded in US as ADRs Rise in Thursday Trading

MT Newswires • 2026-06-11T15:09:49Z

Autolus Therapeutics (AUTL) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Zacks • 2026-06-10T13:55:02Z

European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading

MT Newswires • 2026-06-08T15:10:25Z

How The Autolus Therapeutics (AUTL) Investment Story Is Evolving With A Steady Analyst Outlook

Simply Wall St. • 2026-06-05T23:10:38Z

European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading; Rise for Week

MT Newswires • 2026-06-05T15:06:40Z

European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading

MT Newswires • 2026-06-04T15:08:32Z

European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading

MT Newswires • 2026-06-03T15:10:58Z

Autolus Therapeutics PLC Sponsored ADR (AUTL) Just Flashed Golden Cross Signal: Do You Buy?

Zacks • 2026-06-01T13:55:02Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Reconciled Cost Of Revenue	$96,369,000	$11,387,000	$0	-
Cost Of Revenue	$96,369,000	$11,387,000	$0	-
Total Revenue	$75,388,000	$10,120,000	$1,698,000	$6,194,000
Operating Revenue	$75,388,000	$10,120,000	$1,698,000	$6,194,000
Expenses
Interest Expense	$36,670,000	$9,294,000	$45,067,000	$8,905,000
Total Expenses	$345,932,000	$251,546,000	$177,226,000	$149,087,000
Other Income Expense	$2,678,000	$-769,000	$-1,312,000	$1,523,000
Other Non Operating Income Expenses	$515,000	$220,000	$222,000	$2,038,000
Net Non Operating Interest Income Expense	$-17,690,000	$23,061,000	$-31,562,000	$-7,197,000
Interest Expense Non Operating	$36,670,000	$9,294,000	$45,067,000	$8,905,000
Operating Expense	$249,563,000	$240,159,000	$177,226,000	$149,087,000
General And Administrative Expense	-	-	$46,745,000	$31,899,000
Other Operating Expenses	-	-	-	$-166,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-287,528,000	$-220,662,000	$-208,383,000	$-148,839,000
Net Interest Income	$-17,690,000	$23,061,000	$-31,562,000	$-7,197,000
Interest Income	$18,980,000	$32,355,000	$13,505,000	$1,708,000
Normalized Income	$-289,236,770	$-219,880,690	$-206,849,140	$-148,432,150
Net Income From Continuing And Discontinued Operation	$-287,528,000	$-220,662,000	$-208,383,000	$-148,839,000
Total Operating Income As Reported	$-270,544,000	$-241,426,000	$-179,701,000	-
Net Income Common Stockholders	$-287,528,000	$-220,662,000	$-208,383,000	$-148,839,000
Net Income	$-287,528,000	$-220,662,000	$-208,383,000	$-148,839,000
Net Income Including Noncontrolling Interests	$-287,528,000	$-220,662,000	$-208,383,000	$-148,839,000
Net Income Continuous Operations	$-287,528,000	$-220,662,000	$-208,383,000	$-148,839,000
Pretax Income	$-285,556,000	$-219,134,000	$-208,402,000	$-148,567,000
Interest Income Non Operating	$18,980,000	$32,355,000	$13,505,000	$1,708,000
Operating Income	$-270,544,000	$-241,426,000	$-175,528,000	$-142,893,000
Gross Profit	$-20,981,000	$-1,267,000	$1,698,000	-
Special Income Charges	-	$-637,000	$-4,173,000	$-515,000
Per Share
Diluted EPS	$-1.08	$-0.86	$-1.20	$-1.57
Basic EPS	$-1.08	$-0.86	$-1.20	$-1.57
Other
Tax Effect Of Unusual Items	$454,230	$-207,690	$-140	$-108,150
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-241,235,000	$-201,135,000	$-155,236,000	$-131,725,000
Total Unusual Items	$2,163,000	$-989,000	$-1,534,000	$-515,000
Total Unusual Items Excluding Goodwill	$2,163,000	$-989,000	$-1,534,000	$-515,000
Reconciled Depreciation	$9,814,000	$7,716,000	$6,565,000	$7,422,000
EBITDA (Bullshit earnings)	$-239,072,000	$-202,124,000	$-156,770,000	$-132,240,000
EBIT	$-248,886,000	$-209,840,000	$-163,335,000	$-139,662,000
Diluted Average Shares	$266,138,224	$255,161,038	$173,941,926	$94,993,400
Basic Average Shares	$266,138,224	$255,161,038	$173,941,926	$94,993,400
Diluted NI Availto Com Stockholders	$-287,528,000	$-220,662,000	$-208,383,000	$-148,839,000
Tax Provision	$1,972,000	$1,528,000	$-19,000	$272,000
Gain On Sale Of Security	$2,163,000	$-989,000	$2,639,000	-
Research And Development	$117,689,000	$138,436,000	$130,481,000	$117,354,000
Selling General And Administration	$131,874,000	$101,723,000	$46,745,000	$31,899,000
Gain On Sale Of Ppe	-	$-223,000	$-3,791,000	$-515,000
Impairment Of Capital Assets	-	$414,000	$382,000	$0
Other Gand A	-	-	$46,745,000	$31,899,000

Fetched: 2026-06-15

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$158,320,000	$414,952,000	$111,474,000	$298,674,000
Total Assets	$589,068,000	$782,725,000	$375,381,000	$490,274,000
Total Non Current Assets	$153,153,000	$121,796,000	$100,079,000	$64,503,000
Other Non Current Assets	$249,000	$170,000	$380,000	$2,176,000
Non Current Prepaid Assets	$1,032,000	$963,000	$983,000	$1,832,000
Non Current Deferred Assets	$3,560,000	$3,239,000	$3,063,000	$2,076,000
Non Current Deferred Taxes Assets	$3,560,000	$3,239,000	$3,063,000	$2,076,000
Goodwill And Other Intangible Assets	$19,809,000	$12,373,000	$0	$0
Other Intangible Assets	$19,809,000	$12,373,000	-	-
Current Assets	$435,915,000	$660,929,000	$275,302,000	$425,771,000
Current Deferred Assets	$3,429,000	$2,320,000	$1,787,000	$1,494,000
Restricted Cash	$1,503,000	$1,425,000	$769,000	$325,000
Prepaid Assets	$21,275,000	$15,212,000	$8,638,000	$12,337,000
Inventory	$33,209,000	$4,138,000	$0	-
Receivables	$75,789,000	$48,240,000	$24,542,000	$28,976,000
Other Receivables	$47,314,000	$39,663,000	$20,663,000	$26,154,000
Taxes Receivable	$3,577,000	$5,996,000	$2,771,000	$2,701,000
Accrued Interest Receivable	$874,000	$2,566,000	$999,000	-
Accounts Receivable	$24,024,000	$15,000	$109,000	$121,000
Cash Cash Equivalents And Short Term Investments	$300,710,000	$588,023,000	$239,566,000	$382,436,000
Cash And Cash Equivalents	$104,132,000	$227,380,000	$239,566,000	$382,436,000
Other Current Assets	-	$1,571,000	-	$203,000
Cash Financial	-	-	-	-
Debt
Total Debt	$71,387,000	$52,629,000	$52,967,000	$24,256,000
Long Term Debt And Capital Lease Obligation	$66,822,000	$49,631,000	$47,914,000	$19,218,000
Current Debt And Capital Lease Obligation	$4,565,000	$2,998,000	$5,053,000	$5,038,000
Liabilities
Total Liabilities Net Minority Interest	$410,939,000	$355,400,000	$263,907,000	$191,600,000
Total Non Current Liabilities Net Minority Interest	$337,499,000	$294,657,000	$219,170,000	$145,234,000
Other Non Current Liabilities	$270,200,000	$244,600,000	$170,899,000	$125,900,000
Tradeand Other Payables Non Current	$477,000	$426,000	$357,000	$116,000
Current Liabilities	$73,440,000	$60,743,000	$44,737,000	$46,366,000
Other Current Liabilities	$17,019,000	$3,979,000	$533,000	$393,000
Payables And Accrued Expenses	$25,632,000	$34,085,000	$24,394,000	$30,754,000
Payables	$3,083,000	$5,563,000	$103,000	$531,000
Total Tax Payable	$0	$3,594,000	$0	-
Accounts Payable	$3,083,000	$1,969,000	$103,000	$531,000
Equity
Common Stock Equity	$178,129,000	$427,325,000	$111,474,000	$298,674,000
Total Equity Gross Minority Interest	$178,129,000	$427,325,000	$111,474,000	$298,674,000
Stockholders Equity	$178,129,000	$427,325,000	$111,474,000	$298,674,000
Other Equity Interest	$118,000	$118,000	$118,000	$118,000
Gains Losses Not Affecting Retained Earnings	$-5,356,000	$-29,174,000	$-28,992,000	$-38,898,000
Other Equity Adjustments	$-5,356,000	$-29,174,000	$-28,992,000	$-38,898,000
Retained Earnings	$-1,386,752,000	$-1,099,224,000	$-878,562,000	$-670,179,000
Other
Ordinary Shares Number	$266,143,286	$266,121,689	$174,101,361	$173,074,510
Share Issued	$266,143,286	$266,121,689	$174,101,361	$173,074,510
Tangible Book Value	$158,320,000	$414,952,000	$111,474,000	$298,674,000
Invested Capital	$178,129,000	$427,325,000	$111,474,000	$298,674,000
Working Capital	$362,475,000	$600,186,000	$230,565,000	$379,405,000
Capital Lease Obligations	$71,387,000	$52,629,000	$52,967,000	$24,256,000
Total Capitalization	$178,129,000	$427,325,000	$111,474,000	$298,674,000
Additional Paid In Capital	$1,570,107,000	$1,555,593,000	$1,018,902,000	$1,007,625,000
Capital Stock	$12,000	$12,000	$8,000	$8,000
Common Stock	$12,000	$12,000	$8,000	$8,000
Long Term Capital Lease Obligation	$66,822,000	$49,631,000	$47,914,000	$19,218,000
Current Capital Lease Obligation	$4,565,000	$2,998,000	$5,053,000	$5,038,000
Pensionand Other Post Retirement Benefit Plans Current	$26,224,000	$19,681,000	$14,757,000	$10,181,000
Current Accrued Expenses	$22,549,000	$28,522,000	$24,291,000	$30,223,000
Net PPE	$128,503,000	$105,051,000	$95,653,000	$58,419,000
Accumulated Depreciation	$-44,394,000	$-34,618,000	$-28,774,000	$-25,647,000
Gross PPE	$172,897,000	$139,669,000	$124,427,000	$84,066,000
Leases	$15,762,000	$14,116,000	$12,728,000	$11,688,000
Construction In Progress	$27,075,000	$19,638,000	$12,539,000	$13,186,000
Other Properties	$120,526,000	$97,226,000	$93,023,000	$54,398,000
Machinery Furniture Equipment	$9,534,000	$8,689,000	$6,137,000	$4,794,000
Properties	$0	$0	$0	$0
Finished Goods	$5,395,000	$140,000	$0	-
Work In Process	$3,633,000	$16,000	$0	-
Raw Materials	$24,181,000	$3,982,000	$0	-
Other Short Term Investments	$196,578,000	$360,643,000	$0	-
Treasury Shares Number	-	-	$0	-

Fetched: 2026-06-15

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-310,700,000	$-241,090,000	$-156,573,000	$-123,149,000
Operating Activities
Operating Cash Flow	$-283,568,000	$-206,271,000	$-145,587,000	$-112,308,000
Cash Flow From Continuing Operating Activities	$-283,568,000	$-206,271,000	$-145,587,000	$-112,308,000
Operating Gains Losses	$-3,153,000	$2,121,000	$-3,813,000	$4,511,000
Investing Activities
Capital Expenditure	$-27,132,000	$-34,819,000	$-10,986,000	$-10,841,000
Investing Cash Flow	$158,458,000	$-394,552,000	$-10,986,000	$-10,841,000
Cash Flow From Continuing Investing Activities	$158,458,000	$-394,552,000	$-10,986,000	$-10,841,000
Financing Activities
Issuance Of Capital Stock	$0	$549,977,000	$0	$163,854,000
Financing Cash Flow	$-4,339,000	$589,554,000	$-883,000	$223,610,000
Cash Flow From Continuing Financing Activities	$-4,339,000	$589,554,000	$-883,000	$223,610,000
Net Other Financing Charges	$-4,339,000	$38,975,000	$-910,000	$59,639,000
Net Common Stock Issuance	$0	$549,977,000	$0	$163,854,000
Common Stock Issuance	$0	$549,977,000	$0	$163,854,000
Other
Income Tax Paid Supplemental Data	$1,968,000	$2,391,000	$551,000	$471,000
End Cash Position	$105,635,000	$228,805,000	$240,335,000	$382,761,000
Beginning Cash Position	$228,805,000	$240,335,000	$382,761,000	$310,676,000
Effect Of Exchange Rate Changes	$6,279,000	$-261,000	$15,030,000	$-28,376,000
Changes In Cash	$-129,449,000	$-11,269,000	$-157,456,000	$100,461,000
Proceeds From Stock Option Exercised	$0	$602,000	$27,000	$117,000
Net Investment Purchase And Sale	$185,590,000	$-359,733,000	$0	-
Sale Of Investment	$428,209,000	$0	-	-
Purchase Of Investment	$-242,619,000	$-359,733,000	$0	-
Net Intangibles Purchase And Sale	$-8,089,000	$-12,744,000	$0	-
Purchase Of Intangibles	$-8,089,000	$-12,744,000	$0	-
Net PPE Purchase And Sale	$-19,043,000	$-22,075,000	$-10,986,000	$-10,841,000
Purchase Of PPE	$-19,043,000	$-22,075,000	$-10,986,000	$-10,841,000
Change In Working Capital	$-51,989,000	$-23,655,000	$292,000	$536,000
Change In Other Current Liabilities	$14,645,000	$-369,000	$-13,555,000	$-4,687,000
Change In Payables And Accrued Expense	$2,340,000	$13,524,000	$489,000	$16,029,000
Change In Accrued Expense	$1,040,000	$11,934,000	$998,000	$16,007,000
Change In Payable	$1,300,000	$1,590,000	$-509,000	$22,000
Change In Account Payable	$1,300,000	$1,590,000	$-509,000	$22,000
Change In Prepaid Assets	$-4,566,000	$-32,581,000	$13,358,000	$-10,806,000
Change In Inventory	$-40,250,000	$-4,229,000	$0	-
Change In Receivables	$-24,158,000	$0	-	-
Changes In Account Receivables	$-24,158,000	$0	-	-
Other Non Cash Items	$22,508,000	$12,508,000	$49,152,000	$12,316,000
Stock Based Compensation	$14,438,000	$15,472,000	$11,204,000	$12,014,000
Asset Impairment Charge	$12,628,000	$414,000	$382,000	$0
Deferred Tax	$-286,000	$-185,000	$-986,000	$-268,000
Deferred Income Tax	$-286,000	$-185,000	$-986,000	$-268,000
Depreciation Amortization Depletion	$9,814,000	$7,716,000	$6,565,000	$7,422,000
Depreciation And Amortization	$9,814,000	$7,716,000	$6,565,000	$7,422,000
Amortization Cash Flow	$1,518,000	$162,000	$0	-
Amortization Of Intangibles	$1,518,000	$162,000	$0	-
Depreciation	$8,296,000	$7,554,000	$6,565,000	-
Net Foreign Currency Exchange Gain Loss	$-3,167,000	$1,898,000	$-7,604,000	$3,996,000
Gain Loss On Sale Of PPE	$14,000	$223,000	$3,791,000	$515,000
Net Income From Continuing Operations	$-287,528,000	$-220,662,000	$-208,383,000	$-148,839,000
Change In Other Current Assets	-	-	-	-

Fetched: 2026-06-15